首页> 外文期刊>The Canadian journal of cardiology >Expedited blood pressure control with initial angiotensin II antagonist/diuretic therapy compared with stepped-care therapy in patients with ambulatory systolic hypertension.
【24h】

Expedited blood pressure control with initial angiotensin II antagonist/diuretic therapy compared with stepped-care therapy in patients with ambulatory systolic hypertension.

机译:与非门诊收缩期高血压患者的逐步治疗相比,采用初始血管紧张素II拮抗剂/利尿剂可加快血压控制。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: The present study investigated whether initiating therapy with a combination of losartan (L) and hydrochlorothiazide (HCTZ) allows for faster blood pressure (BP) control and fewer medications than the usual stepped-care approach in patients with stage 2 or 3 hypertension and ambulatory systolic hypertension. METHODS: Patients with a mean daytime systolic ambulatory BP (ABP) of 135 mmHg or higher were randomly assigned to receive L 50 mg plus HCTZ 12.5 mg titrated to L 100 mg plus HCTZ 25 mg versus HCTZ 12.5 mg plus atenolol 50 mg. Amlodipine 5 mg was then added, if needed, to achieve a BP goal of less than 130 mmHg. Treatment titration was based on ABP. RESULTS: Significantly more patients randomly assigned to L/HCTZ (63.5%) than stepped-care (37.5%; P=0.008) achieved the primary end point (daytime systolic BP of less than 130 mmHg). Initial L/HCTZ induced significantly greater decreases in ABP during each 24 h period after six weeks of therapy. Although reductions in systolic and diastolicABP were not statistically different at the end of the study, ABP reduction was significantly greater (P<0.001) with the L/HCTZ-based regimen. Twice as many patients in the L/HCTZ group achieved the goal ABP with no more than two drugs (30.0% versus 14.7%; P=0.03). Moreover, tolerability was significantly better (P=0.006) in the L/HCTZ group, with a 40.0% incidence of adverse events, versus 65.6% in the stepped-care group. CONCLUSION: Initiating antihypertensive therapy with the combination of L/HCTZ in patients with stage 2 or 3 hypertension and ambulatory systolic hypertension reaches a target BP faster in a higher proportion of patients, with fewer adverse events and less need for a third drug regimen than the conventional stepped-care approach.
机译:目的:本研究调查了在患有2或3期高血压和2型高血压的患者中,氯沙坦(L)和氢氯噻嗪(HCTZ)的联合治疗是否比通常的分步护理方法能够更快地控制血压(BP)和减少用药。动态收缩期高血压。方法:将平均白天收缩期动态血压(ABP)为135 mmHg或更高的患者随机分配为接受L 50 mg加HCTZ 12.5 mg滴定至L 100 mg加HCTZ 25 mg与HCTZ 12.5 mg加阿替洛尔50 mg。如果需要,然后加入5毫克氨氯地平以达到BP目标小于130毫米汞柱。处理滴定基于ABP。结果:达到主要终点(白天收缩压小于130 mmHg)的患者,随机分配到L / HCTZ(63.5%)的患者明显多于逐步护理(37.5%; P = 0.008)。最初的L / HCTZ疗法在治疗六周后的每24小时内诱导的ABP降低幅度更大。尽管在研究结束时收缩压和舒张压ABP的降低无统计学差异,但基于L / HCTZ的方案的ABP降低显着更大(P <0.001)。 L / HCTZ组中使用不超过两种药物达到目标ABP的人数是其的两倍(30.0%对14.7%; P = 0.03)。此外,L / HCTZ组的耐受性明显更好(P = 0.006),不良事件发生率为40.0%,而阶梯式护理组为65.6%。结论:在较高比例的患者中,L / HCTZ联合L / HCTZ联合治疗2或3期高血压和动态收缩期高血压的患者达到目标BP的速度更快,不良事件更少,与第三种药物治疗相比,其对第三种药物的需求更少传统的分步护理方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号